The Indian IPO market continues to remain active, especially in the SME IPO segment. One of the upcoming SME public issues drawing investor attention is the Accretion Nutraveda IPO 2026. The company operates in the nutraceutical and wellness industry, a sector witnessing strong long-term growth due to rising health awareness and demand for preventive healthcare solutions.
In this article, we provide a complete Accretion Nutraveda IPO review, covering IPO dates, price band, lot size, financial overview, strengths, risks, GMP outlook, and whether investors should consider applying.
has-alpha-channel-opacity"/>
About Accretion Nutraveda Limited
Accretion Nutraveda Limited is engaged in the manufacturing, marketing, and distribution of nutraceutical and herbal wellness products. The company focuses on combining Ayurveda with modern nutritional science to create products that support immunity, overall wellness, and lifestyle health.
Key Product Categories
Dietary supplements
Herbal capsules and powders
Immunity boosters
Wellness and lifestyle nutrition products
With increasing consumer preference for natural and preventive healthcare, the company aims to expand its footprint across India.
Nutraceutical Industry Overview
India’s nutraceutical market is growing at a CAGR of 10–12%, driven by:
Rising health consciousness after COVID-19
Urban lifestyle diseases
Increasing disposable income
Strong demand for herbal and ayurvedic products
Government support through AYUSH initiatives
However, the industry is also highly competitive, with the presence of large FMCG, pharma companies, and numerous SME players.
Accretion Nutraveda IPO Details
Below are the key details of the Accretion Nutraveda IPO:
Particular
Details
IPO Name
Accretion Nutraveda IPO
Issue Type
SME IPO
Issue Size
₹24.77 Crore
Price Band
₹122 – ₹129 per share
Lot Size
1,000 shares
Minimum Investment
₹2,44,000
IPO Open Date
28 January 2026
IPO Close Date
30 January 2026
Tentative Allotment
02 February 2026
Tentative Listing
04 February 2026
Exchange
SME Platform
IPO Document
RHP Available
Objectives of the IPO Issue
The company plans to utilize IPO proceeds for:
Meeting working capital requirements
Expansion of business operations
Strengthening marketing and distribution
General corporate purposes
For SME companies, working capital infusion is crucial for scaling operations and improving efficiency.
Financial Performance Overview
As per information disclosed in the Red Herring Prospectus (RHP), Accretion Nutraveda Limited has shown:
Steady revenue growth
Improving operational efficiency
Focus on higher-margin nutraceutical products
Key Financial Metrics to Track
Revenue growth trend
EBITDA margins
Net profit consistency
Return on Net Worth (RoNW)
Debt-to-equity ratio
📌 Note: Investors should carefully review audited financials in the RHP before applying.
Strengths of Accretion Nutraveda IPO
1. High-Growth Sector
The nutraceutical and wellness industry offers strong long-term growth potential.
2. Diversified Product Portfolio
Multiple product categories reduce dependency on a single revenue
source.
3. Rising Health Awareness
Growing demand for immunity and wellness products supports consistent sales.
4. Small Issue Size
Lower issue size can sometimes lead to better listing interest if subscription is strong.
Risks and Challenges
1. SME IPO Volatility
SME IPOs are less liquid and more volatile than mainboard IPOs.
2. High Minimum Investment
Retail investors need to invest at least ₹2.44 lakh, which limits participation.
3. Intense Competition
Large FMCG and pharma companies pose a competitive threat.
4. Regulatory Risk
The nutraceutical business is regulated by FSSAI, and compliance is critical.
Accretion Nutraveda IPO GMP (Grey Market Premium)
The Grey Market Premium (GMP) reflects unofficial market sentiment before listing:
Positive GMP → Possible listing gains
Flat or negative GMP → Limited short-term upside
⚠ Disclaimer: GMP is speculative and should not be the sole factor for investment decisions.
Who Should Apply for Accretion Nutraveda IPO?
Suitable For
Investors with high risk appetite
SME IPO traders seeking listing gains
Experienced investors understanding SME risks
Not Suitable For
Conservative investors
First-time IPO investors
Long-term investors seeking stable returns
Listing Expectations
If market sentiment remains positive and subscription levels are healthy, the IPO may:
List at a moderate premium
Experience volatility in early trading
Post-listing performance will depend on:
Quarterly financial results
Business expansion
Overall SME market sentiment
Important IPO Dates
IPO Opens: 28 January 2026
IPO Closes: 30 January 2026
Allotment Date: 02 February 2026
Listing Date: 04 February 2026
Final Verdict: Should You Apply for Accretion Nutraveda IPO?
The Accretion Nutraveda IPO 2026 provides exposure to a fast-growing wellness sector but comes with SME-specific risks. Investors should carefully analyze financials, GMP trends, and subscription data before applying.
👉 High-risk investors may consider this IPO for short-term opportunities, while long-term investors should wait for post-listing performance.
FAQs – Accretion Nutraveda IPO
Q1. What is the price band of Accretion
Nutraveda IPO?
The price band is ₹122 to ₹129 per share.
Q2. What is the minimum investment required?
The minimum investment is ₹2,44,000 (1 lot = 1,000 shares).
Q3. Is Accretion Nutraveda IPO an SME IPO?
Yes, it is listed on the SME platform.
Q4. Where can I check the IPO allotment status?
Allotment status can be checked on the registrar’s website or through your broker.
Q5. Is Accretion Nutraveda IPO good for long-term investment?
SME IPOs carry higher risk. Long-term investors should track post-listing performance before investing.
📌 Disclaimer: This article is for educational purposes only and does not constitute investment advice. Always consult a financial advisor before investing.
